| Year |
Citation |
Score |
| 2020 |
Miyamoto DT, Lee RJ. PIK Carefully, AKT Accordingly: Towards Precision Medicine in Prostate Cancer. European Urology. PMID 32900554 DOI: 10.1016/J.Eururo.2020.08.034 |
0.318 |
|
| 2020 |
Naeem A, Dakshanamurthy S, Walthieu H, Parasido E, Avantaggiati M, Tricoli L, Kumar D, Lee RJ, Feldman A, Noon MS, Byers S, Rodriguez O, Albanese C. Predicting new drug indications for prostate cancer: The integration of an in silico proteochemometric network pharmacology platform with patient-derived primary prostate cells. The Prostate. PMID 32761925 DOI: 10.1002/Pros.24050 |
0.486 |
|
| 2019 |
Meric-Bernstam F, Lee RJ, Carthon BC, Iliopoulos O, Mier JW, Patel MR, Tannir NM, Owonikoko TK, Haas NB, Voss MH, Harding JJ, Srinivasan R, Shapiro G, Telli ML, Munster PN, et al. CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study. Journal of Clinical Oncology. 37: 549-549. DOI: 10.1200/Jco.2019.37.7_Suppl.549 |
0.305 |
|
| 2019 |
Hwang W, Pleskow H, Czapla JAA, Fisher R, Kamran S, Lee R, Saylor P, Zietman A, Silvia B, Ting D, Maheswaran S, Haber D, Efstathiou J, Miyamoto D. Integrated Gene Expression Score in Circulating Tumor Cells to Predict Treatment Response in Muscle-Invasive Bladder Cancer International Journal of Radiation Oncology*Biology*Physics. 105: E663. DOI: 10.1016/J.Ijrobp.2019.06.1060 |
0.316 |
|
| 2018 |
Tricoli L, Naeem A, Parasido E, Mikhaiel JP, Choudhry MU, Berry DL, Abdelgawad IA, Lee RJ, Feldman AS, Ihemelandu C, Avantaggiati M, Kumar D, Byers S, Gallagher R, Wulfkuhle J, et al. Characterization of the effects of defined, multidimensional culture conditions on conditionally reprogrammed primary human prostate cells. Oncotarget. 9: 2193-2207. PMID 29416764 DOI: 10.18632/Oncotarget.23363 |
0.523 |
|
| 2018 |
Miyamoto DT, Lee RJ, Kalinich M, LiCausi J, Zheng Y, Chen T, Milner JD, Emmons E, Ho U, Broderick K, Silva E, Javaid S, Kwan TT, Hong X, Dahl DM, et al. An RNA-based digital circulating tumor cell signature is predictive of drug response and early dissemination in prostate cancer. Cancer Discovery. PMID 29301747 DOI: 10.1158/2159-8290.Cd-16-1406 |
0.351 |
|
| 2018 |
Tannir NM, Fan AC, Lee RJ, Carthon BC, Iliopoulos O, Mier JW, Patel MR, Meric-Bernstam F, DeMichele A, Voss MH, Harding JJ, Srinivasan R, Shapiro G, Telli ML, Munster PN, et al. Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC). Journal of Clinical Oncology. 36: 603-603. DOI: 10.1200/Jco.2018.36.6_Suppl.603 |
0.302 |
|
| 2017 |
Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, ... Lee RJ, et al. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology. PMID 29258679 DOI: 10.1016/J.Eururo.2017.11.038 |
0.305 |
|
| 2017 |
Zheng Y, Miyamoto DT, Wittner BS, Sullivan JP, Aceto N, Jordan NV, Yu M, Karabacak NM, Comaills V, Morris R, Desai R, Desai N, Emmons E, Milner JD, Lee RJ, et al. Expression of β-globin by cancer cells promotes cell survival during blood-borne dissemination. Nature Communications. 8: 14344. PMID 28181495 DOI: 10.1038/Ncomms14344 |
0.327 |
|
| 2017 |
Dewal N, He Y, Lee RJ, Schrock AB, Chung J, Hoimes C, Chalmers ZR, Frampton GM, Sun JX, Lara PN, Agrawal N, Matthew P, Stephens PJ, Miller VA, Ross JS, et al. Abstract 3394: CGP identifies largely non-overlapping high tumor mutational burden and HRD genomic alterations in 721 clinically advanced prostate acinar adenocarcinoma cases Cancer Research. 77: 3394-3394. DOI: 10.1158/1538-7445.Am2017-3394 |
0.328 |
|
| 2016 |
Miyamoto DT, Lee RJ. Cell-free and circulating tumor cell-based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine? Urologic Oncology. PMID 27771279 DOI: 10.1016/J.Urolonc.2016.09.001 |
0.349 |
|
| 2016 |
Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, et al. Prostate Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 19-30. PMID 26733552 DOI: 10.6004/Jnccn.2016.0004 |
0.3 |
|
| 2016 |
Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, Desai R, Brannigan BW, Arora KS, Dahl DM, Sequist LV, Smith MR, Kapur R, Wu C, Shioda T, et al. Abstract IA09: Single cell RNA-sequencing of circulating tumor cells Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pmsclingen15-Ia09 |
0.371 |
|
| 2016 |
Saylor PJ, Lee RJ, Arora KS, Ting DT, Deshpande V, Rivera MN, Hu R, Wu C, Miyamoto DT. Abstract 4947: Branched chain RNAin situhybridization for the detection of androgen receptor splice variants within archival prostate cancer tissue Cancer Research. 76: 4947-4947. DOI: 10.1158/1538-7445.Am2016-4947 |
0.304 |
|
| 2015 |
Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, Desai R, Fox DB, Brannigan BW, Trautwein J, Arora KS, Desai N, Dahl DM, Sequist LV, Smith MR, et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science (New York, N.Y.). 349: 1351-6. PMID 26383955 DOI: 10.1126/Science.Aab0917 |
0.356 |
|
| 2015 |
Miyamoto D, Zheng Y, Wittner B, Lee R, Zhu H, Broderick K, Desai R, Brannigan B, Arora K, Dahl D, Sequist L, Smith M, Kapur R, Wu C, Shioda T, et al. Single Cell RNA Profiling of Circulating Tumor Cells in Patients With Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 93: S104. DOI: 10.1016/J.Ijrobp.2015.07.250 |
0.345 |
|
| 2014 |
Ringer L, Sirajuddin P, Tricoli L, Waye S, Choudhry MU, Parasido E, Sivakumar A, Heckler M, Naeem A, Abdelgawad I, Liu X, Feldman AS, Lee RJ, Wu CL, Yenugonda V, et al. The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells. Oncotarget. 5: 10678-91. PMID 25296977 DOI: 10.18632/Oncotarget.2528 |
0.657 |
|
| 2014 |
Miyamoto DT, Sequist LV, Lee RJ. Circulating tumour cells-monitoring treatment response in prostate cancer. Nature Reviews. Clinical Oncology. 11: 401-12. PMID 24821215 DOI: 10.1038/Nrclinonc.2014.82 |
0.322 |
|
| 2014 |
Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, ... Lee RJ, et al. Prostate cancer, version 2.2014. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 686-718. PMID 24812137 DOI: 10.6004/Jnccn.2014.0072 |
0.315 |
|
| 2014 |
Pollock CB, McDonough S, Wang VS, Lee H, Ringer L, Li X, Prandi C, Lee RJ, Feldman AS, Koltai H, Kapulnik Y, Rodriguez OC, Schlegel R, Albanese C, Yarden RI. Strigolactone analogues induce apoptosis through activation of p38 and the stress response pathway in cancer cell lines and in conditionally reprogrammed primary prostate cancer cells. Oncotarget. 5: 1683-98. PMID 24742967 DOI: 10.18632/Oncotarget.1849 |
0.531 |
|
| 2014 |
Lee RJ, Smith MR. Cabozantinib and prostate cancer: inhibiting seed and disrupting soil? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 525-7. PMID 24284057 DOI: 10.1158/1078-0432.Ccr-13-2636 |
0.329 |
|
| 2014 |
Mehta AN, Willey C, Crowley M, Anderson J, Chen D, Crossman D, Necchi A, Lorenzo Gd, Eigl BJ, Lee RJ, Harshman LC, Dorff TB, Galsky MD, Milowsky MI, Bolger G, et al. Integrated comprehensive high-throughput kinomics profiling and whole exome sequencing of penile squamous cell cancer (PSCC). Journal of Clinical Oncology. 32: 383-383. DOI: 10.1200/Jco.2014.32.4_Suppl.383 |
0.34 |
|
| 2013 |
Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, et al. Prostate cancer, version 1.2014. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 1471-9. PMID 24335682 DOI: 10.6004/Jnccn.2013.0174 |
0.32 |
|
| 2013 |
Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J, Kimura A, Sengupta S, Stott SL, Karabacak NM, Barber TA, ... ... Lee RJ, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Science Translational Medicine. 5: 179ra47. PMID 23552373 DOI: 10.1126/Scitranslmed.3005616 |
0.351 |
|
| 2013 |
Lee RJ, Smith MR. Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer Journal (Sudbury, Mass.). 19: 90-8. PMID 23337762 DOI: 10.1097/Ppo.0B013E318281E280 |
0.323 |
|
| 2013 |
Sonpavde G, Pagliaro LC, Buonerba C, Dorff TB, Lee RJ, Lorenzo GD. Penile cancer: current therapy and future directions Annals of Oncology. 24: 1179-1189. PMID 23293117 DOI: 10.1093/Annonc/Mds635 |
0.307 |
|
| 2012 |
Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu CL, Sequist LV, Smith MR, Ramaswamy S, et al. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discovery. 2: 995-1003. PMID 23093251 DOI: 10.1158/2159-8290.Cd-12-0222 |
0.341 |
|
| 2011 |
Saylor PJ, Lee RJ, Smith MR. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3705-14. PMID 21860001 DOI: 10.1200/Jco.2010.34.4994 |
0.316 |
|
| 2011 |
Lee RJ, Saylor PJ, Smith MR. Treatment and prevention of bone complications from prostate cancer. Bone. 48: 88-95. PMID 20621630 DOI: 10.1016/J.Bone.2010.05.038 |
0.305 |
|
| 2010 |
Lee RJ, Saylor PJ, Smith MR. Contemporary therapeutic approaches targeting bone complications in prostate cancer. Clinical Genitourinary Cancer. 8: 29-36. PMID 21208853 DOI: 10.3816/Cgc.2010.N.005 |
0.314 |
|
| 2010 |
Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP, Gilman AJ, Lord JB, Winokur D, Springer S, ... ... Lee RJ, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proceedings of the National Academy of Sciences of the United States of America. 107: 18392-7. PMID 20930119 DOI: 10.1073/Pnas.1012539107 |
0.343 |
|
| 2010 |
Nagrath S, Stott SL, Lee RJ, Yu M, Ulkus LL, Iafrate JA, Smith MR, Tompkins RG, Sequist LV, Haber DA, Maheswaran S, Toner M. Abstract 1136: Detection and characterization of circulating tumor cells in localized and metastatic prostate cancer patients using CTC-Chip microfluidic technology Cancer Research. 70: 1136-1136. DOI: 10.1158/1538-7445.Am10-1136 |
0.352 |
|
| 2009 |
Lee RJ, Stott SL, Nagrath S, Ulkus LE, Dahl DM, Smith MR, Toner M, Maheswaran S, Haber DA. Analyses of circulating tumor cell (CTC) dynamics and treatment response in prostate cancer using the CTC-chip microfluidic device. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5149. PMID 27964441 DOI: 10.1200/Jco.2009.27.15_Suppl.5149 |
0.33 |
|
| 2008 |
Marampon F, Casimiro MC, Fu M, Powell MJ, Popov VM, Lindsay J, Zani BM, Ciccarelli C, Watanabe G, Lee RJ, Pestell RG. Nerve Growth factor regulation of cyclin D1 in PC12 cells through a p21RAS extracellular signal-regulated kinase pathway requires cooperative interactions between Sp1 and nuclear factor-kappaB. Molecular Biology of the Cell. 19: 2566-78. PMID 18367547 DOI: 10.1091/Mbc.E06-12-1110 |
0.738 |
|
| 2006 |
Hulit J, Lee RJ, Li Z, Wang C, Katiyar S, Yang J, Quong AA, Wu K, Albanese C, Russell R, Di Vizio D, Koff A, Thummala S, Zhang H, Harrell J, et al. p27Kip1 repression of ErbB2-induced mammary tumor growth in transgenic mice involves Skp2 and Wnt/beta-catenin signaling. Cancer Research. 66: 8529-41. PMID 16951165 DOI: 10.1158/0008-5472.Can-06-0149 |
0.743 |
|
| 2002 |
Wu K, Wang C, D'Amico M, Lee RJ, Albanese C, Pestell RG, Mani S. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Molecular Cancer Therapeutics. 1: 695-706. PMID 12479366 |
0.638 |
|
| 2002 |
Hulit J, Lee RJ, Russell RG, Pestell RG. ErbB-2-induced mammary tumor growth: The role of cyclin D1 and p27Kip1 Biochemical Pharmacology. 64: 827-836. PMID 12213576 DOI: 10.1016/S0006-2952(02)01145-0 |
0.737 |
|
| 2002 |
Bearss DJ, Lee RJ, Troyer DA, Pestell RG, Windle JJ. Differential effects of p21WAF1/CIP1 deficiency on MMTV-ras and MMTV-myc mammary tumor properties Cancer Research. 62: 2077-2084. PMID 11929828 |
0.486 |
|
| 2002 |
Lee R, Wolda S, Moon E, Esselstyn J, Hertel C, Lerner A. PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP Cellular Signalling. 14: 277-284. PMID 11812656 DOI: 10.1016/S0898-6568(01)00250-9 |
0.335 |
|
| 2000 |
Lerner A, Kim DH, Lee R. The cAMP signaling pathway as a therapeutic target in lymphoid malignancies. Leukemia & Lymphoma. 37: 39-51. PMID 10721768 DOI: 10.3109/10428190009057627 |
0.345 |
|
| 2000 |
Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, Haines GK, Siegel PM, Hung MC, Yarden Y, Horowitz JM, Muller WJ, Pestell RG. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Molecular and Cellular Biology. 20: 672-83. PMID 10611246 DOI: 10.1128/Mcb.20.2.672-683.2000 |
0.676 |
|
| 1999 |
Albanese C, D'Amico M, Reutens AT, Fu M, Watanabe G, Lee RJ, Kitsis RN, Henglein B, Avantaggiati M, Somasundaram K, Thimmapaya B, Pestell RG. Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis Journal of Biological Chemistry. 274: 34186-34195. PMID 10567390 DOI: 10.1074/Jbc.274.48.34186 |
0.771 |
|
| 1999 |
Joyce D, Bouzahzah B, Fu M, Albanese C, D'Amico M, Steer J, Klein JU, Lee RJ, Segall JE, Westwick JK, Der CJ, Pestell RG. Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-kappaB-dependent pathway. The Journal of Biological Chemistry. 274: 25245-9. PMID 10464245 DOI: 10.1074/Jbc.274.36.25245 |
0.636 |
|
| 1999 |
Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ, Arnold A. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocrine Reviews. 20: 501-34. PMID 10453356 DOI: 10.1210/Edrv.20.4.0373 |
0.77 |
|
| 1999 |
Beier F, Leask TA, Haque S, Chow C, Taylor AC, Lee RJ, Pestell RG, Ballock RT, LuValle P. Cell cycle genes in chondrocyte proliferation and differentiation. Matrix Biology : Journal of the International Society For Matrix Biology. 18: 109-20. PMID 10372550 DOI: 10.1016/S0945-053X(99)00009-8 |
0.508 |
|
| 1999 |
Lee RJ, Albanese C, Stenger RJ, Watanabe G, Inghirami G, Haines GK, Webster M, Muller WJ, Brugge JS, Davis RJ, Pestell RG. pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways: A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells Journal of Biological Chemistry. 274: 7341-7350. PMID 10066798 DOI: 10.1074/Jbc.274.11.7341 |
0.67 |
|
| 1998 |
Brown JR, Nigh E, Lee RJ, Ye H, Thompson MA, Saudou F, Pestell RG, Greenberg ME. Fos family members induce cell cycle entry by activating cyclin D1. Molecular and Cellular Biology. 18: 5609-19. PMID 9710644 DOI: 10.1128/Mcb.18.9.5609 |
0.532 |
|
| 1998 |
Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, Siegel P, Muller WJ, Windle JJ, Pestell RG, Lisanti MP. Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. The Journal of Biological Chemistry. 273: 20448-55. PMID 9685399 DOI: 10.1074/Jbc.273.32.20448 |
0.694 |
|
| 1998 |
Westwick JK, Lee RJ, Lambert QT, Symons M, Pestell RG, Der CJ, Whitehead IP. Transforming potential of Dbl family proteins correlates with transcription from the cyclin D1 promoter but not with activation of Jun NH2-terminal kinase, p38/Mpk2, serum response factor, or c-Jun Journal of Biological Chemistry. 273: 16739-16747. PMID 9642229 DOI: 10.1074/Jbc.273.27.16739 |
0.523 |
|
| 1998 |
Watanabe G, Albanese C, Lee RJ, Reutens A, Vairo G, Henglein B, Pestell RG. Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1 Molecular and Cellular Biology. 18: 3212-3222. PMID 9584162 DOI: 10.1128/Mcb.18.6.3212 |
0.768 |
|
| 1997 |
Li X, Hales KH, Watanabe G, Lee RJ, Pestell RG, Hales DB. The effect of tumor necrosis factor-alpha and cAMP on induction of AP-1 activity in MA-10 tumor Leydig cells. Endocrine. 6: 317-24. PMID 9368689 DOI: 10.1007/Bf02820509 |
0.489 |
|
| 1996 |
Watanabe G, Lee RJ, Albanese C, Rainey WE, Batlle D, Pestell RG. Angiotensin II activation of cyclin D1-dependent kinase activity Journal of Biological Chemistry. 271: 22570-22577. PMID 8798425 DOI: 10.1074/Jbc.271.37.22570 |
0.666 |
|
| Show low-probability matches. |